MCAS claims audit (Andra Sitoianu)

01Source identity (from open metadata)

• Full name: Andra Sitoianu
• Credentials: Naturopathic doctor (ND); per Substack metadata, specializes in fertility, nose-to-tail nutrition, food allergy, and "Eat Your Hydration." Self-describes as "independent researcher" and "Food Allergy Mommy."[unverified beyond Substack metadata]
• Primary channel: https://x.com/BioavailableNd
• Secondary channel: https://bioavailablend.substack.com
• Substack subscriber count: 10,000+ (per public Substack metadata)
• Public posts on histamine/MCAS: "Mast Cell Activation Syndrome (MCAS) Protocol" (paid), "From Mouth to Microbiome: How Nickel Can Trigger IBS/IBD Flares" (paid), "The Rosacea Guide" (paid), "The Acne Guide" (paid), "The Lipedema Guide" (paid), "Lipedema: Leaky Gut, Thyroid, Nickel & MCAS" (paid). Multiple X posts on histamine, mast cells, and nnEMF.

02Source quality — library convention applies

Per Source Evaluation Framework, Andra's posts are Rating 2–3 sources (clinical observations from a licensed practitioner with patient-facing case volume, but published without peer review, without primary-source citations, and with strong financial alignment — paid Substack content is a direct revenue stream).

Swipe table →

03Claim-by-claim audit

For the full claim table see Overview - MCAS and Histamine. Summary:

Claims with strong primary-literature support (Rating 4–5)

• MCAS exists as a clinical entity (consensus-1 and consensus-2 both ratified)
• Mast cells release many mediators, not just histamine
• DAO deficiency drives some HIT symptoms; DAO supplementation helps migraine/urticaria/fibromyalgia
• Vitamin C reduces blood histamine in depleted subjects
• Quercetin has mast-cell-stabilizing activity
• Estrogen directly triggers mast cell degranulation in reproductive tissue
• Nickel is a metalloestrogen (Martin et al.)
• Nickel allergy is associated with endometriosis in cohorts
• Stress / CRH activate mast cells and increase intestinal permeability
• Low-histamine diet helps HIT subgroup

Claims that are mechanistic plausibility only (Rating 2–3)

• "Total load / bucket loss of tolerance" as a measurable model
• Mold / CIRS → MCAS (overlap real, causal link thin)
• Nickel as a mast cell activator in non-sensitized hosts
• DAO capacity falling with age → clinical HIT in older adults
• Sleep / circadian disruption worsening mast cell activity
• POTS / hEDS / MCAS clustering (association firmly established, mechanism unclear)
• Long COVID → MCAS (symptom overlap real, full consensus-1 criteria rare)

Claims that are speculative or unsupported (Rating 1)

• ADHD as "a histamine problem"
• nnEMF as a primary MCAS driver
• Organotherapy for MCAS
• Cell salts (biochemic) for MCAS
• Limbic retraining (DNRS) for MCAS — no MCAS-specific trial
• Direct causal link from MCAS to: PCOS, GERD, weight gain/lipedema, eczema in general
• "Beef kidney as a DAO source" via dietary DAO activity

04What is genuinely useful about her work

1. The clinical framing is reasonable. "Total load / bucket" is a useful heuristic for clinicians who have a patient with stacked triggers. It does not require mechanistic proof to be clinically useful.
2. She correctly identifies that H1 antihistamines alone are insufficient for MCAS. This matches mainstream MCAS literature and is worth patients knowing.
3. The emphasis on mold, nickel, hormones, and stress as stacked triggers is consistent with the broad literature showing mast cells respond to all of these signals.
4. Her Substack is a useful discovery channel for what chronic-illness communities are currently discussing. It is not a substitute for primary literature.

05What is problematic

1. Almost no primary literature cited. Claims are presented as clinical truth without supporting PMIDs. This is the most important limitation — patients and clinicians cannot audit the underlying evidence.
2. Paywall on the protocol post. The "MCAS Protocol" post (the central document for her MCAS framework) is gated; the public preview describes "dozens of chemical messengers beyond histamine" but does not give specific dosing, sequencing, or the underlying rationale.
3. Broader-than-supported claims about MCAS driving PCOS, ADHD, GERD, lipedema, etc. Each of these has at most fragmentary evidence.
4. Speculative interventions are presented alongside mainstream ones. Organotherapy, cell salts, and limbic retraining are presented without distinguishing them from evidence-based interventions.
5. No systematic outcome data. this library's Source Evaluation Framework flags this as Rating 1.

06Practical Notes (library usage)

• Use Andra's work as a clinical framework and a discovery channel for what chronic-illness communities are paying attention to.
• Always cross-check specific claims against the primary references listed in Overview - MCAS and Histamine, MCAS - Diagnostic Criteria and Differential, DAO and Histamine Degradation, and MCAS - Drivers and Comorbidities.
• Be especially skeptical of the "MCAS underlies [long condition list]" framing — most of these connections are mechanistic plausibility or single-cohort association, not demonstrated causality.
• Treat her protocols as a layered, total-load approach that may help some patients; not as a validated treatment standard.

07Notes

• A 2024 single-center study of 703 suspected MCAS patients found that only a small minority met consensus-1 MCAS criteria, with most having alternative or comorbid explanations. This is consistent with the experience that the broad consensus-2 framing produces many false-positive diagnoses.[128]
• The chronic-illness community often anchors on a small set of influential practitioners (Andra, Neil Nathan, Jill Carnahan, Ben Weiler for mainstream, Afrin for consensus-2). Each practitioner has a different bias; this library should record the bias, not just the recommendation.

08Connections

09Sources

1. PubMed 38056692PubMed 38056692

10Entry history

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.